September 16, 2009 — Cancer therapies are increasingly being tailored to fit the genetic profile of the patient, but new research suggests that human epidermal growth-factor receptor (HER)2 gene ...

Changes to testing guidelines have doubled the number of patients who test positive for HER2, a protein used to diagnose breast cancer, according to a study published by Mayo Clinic researchers in the ...

Trastuzumab deruxtecan (T-DXd) has redefined the therapeutic landscape for breast cancer since its approval in 2019. Correspondingly, the relevance of HER2 testing beyond the traditional dichotomy of ...

New antibody-drug conjugates (ADCs) can target breast cancers with even the tiniest amount of HER2 expression. The old binary classification of HER2-positive or -negative has evolved into categories ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

Biomarkers are measurable indicators that can be tested to reveal important details about a cancer. Information about these biomarkers can help guide the best treatment for you, predict your response ...

Blood test for breast cancer patients will be performed by Biocept and analyzed by Clarient. Biocept and Clarient have entered a collaboration to commercialize a blood test for circulating tumor cells ...

Pathological analysis of tumor microenvironmental features using deep learning to predict survival of colon carcinomas. A prospective, cross-sectional, multicentre study to evaluate the clinical ...

The VENTANA HER2 (4B5) test is now CE-IVDR approved to aid in the assessment of HER2-ultralow status to identify metastatic breast cancer patients who may be eligible for treatment with ENHERTU. The ...